Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Daamen Marcel, Scheef Lukas, Li Shumei, Grothe Michel J, Gaertner Florian C, Buchert Ralph, Buerger Katharina, Dobisch Laura, Drzezga Alexander, Essler Markus, Ewers Michael, Fliessbach Klaus, Herrera Melendez Ana Lucia, Hetzer Stefan, Janowitz Daniel, Kilimann Ingo, Krause Bernd Joachim, Lange Catharina, Laske Christoph, Munk Matthias H, Peters Oliver, Priller Josef, Ramirez Alfredo, Reimold Matthias, Rominger Axel, Rostamzadeh Ayda, Roeske Sandra, Roy Nina, Scheffler Klaus, Schneider Anja, Spottke Annika, Spruth Eike Jakob, Teipel Stefan J, Wagner Michael, Düzel Emrah, Jessen Frank, Boecker Henning, DELCODE Study Group
Аннотация
OBJECTIVE: To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes.
METHODS: The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses.
RESULTS: Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion.
CONCLUSIONS: The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.